JP Morgan Maintains Overweight on Kala Pharmaceuticals, Lowers Price Target to $14

JP Morgan maintains Kala Pharmaceuticals (NASDAQ:KALA) with a Overweight and lowers the price target from $22 to $14.

Benzinga · 11/08/2019 13:34

JP Morgan maintains Kala Pharmaceuticals (NASDAQ:KALA) with a Overweight and lowers the price target from $22 to $14.